Trials / Completed
CompletedNCT03666923
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-687 for the Treatment of Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- ThromboGenics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | THR-687 dose level 1 | single intravitreal injection of THR-687 dose level 1 |
| DRUG | THR-687 dose level 2 | single intravitreal injection of THR-687 dose level 2 |
| DRUG | THR-687 dose level 3 | single intravitreal injection of THR-687 dose level 3 |
Timeline
- Start date
- 2018-09-17
- Primary completion
- 2019-11-20
- Completion
- 2019-11-20
- First posted
- 2018-09-12
- Last updated
- 2020-01-22
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03666923. Inclusion in this directory is not an endorsement.